The independent prognostic value of HPV genotype is confirmed in this study. The prognostic models could be useful in counseling patients and stratifying patients in future clinical trials.

Human papillomavirus (HPV), a small, nonenveloped, double-stranded DNA virus, is established as the key etiological factor in cervical neoplasms (24,29,30). More than 90% of cervical neoplasms are attributed to HPV infection. Persistence of high-risk HPV types is a major risk factor for the development of high-risk cervical intraepithelial neoplasia (CIN) (9). Although the regression of HPV infection commonly takes place within 3 years, compelling evidence indicated that a small but definite fraction of the infected population is at risk for developing invasive cervical cancer after many years or decades of a long latency period of primary infection (3,10,14).Currently, HPV DNA testing has played a triage role for atypical squamous cells of undetermined significance (ASCUS), primary screening in conjunction with cytology for the detection of cervical cancer and CIN, and follow-up in a variety of clinical settings (4,15,16,18,25).HPV DNA detection by the FDA-approved Hybrid Capture II HPV DNA test (HCII) (Digene Corporation, Gaithersburg, MD) is the most widely used method. The HCII system, a commercial liquid hybridization kit using RNA probes against HPV DNA genomic targets followed by signal amplification, has been validated for its reproducibility in HPV DNA detection (18,26,29). Thirteen carcinogenic types implicated in the pathogenesis of high-grade squamous intraepithelial lesions (HSILs) and invasive cancer, such as HPV type 16 (HPV

Admission dehydration is associated with worse discharge outcomes and higher admission costs in acute ischaemic stroke but not in hemorrhagic stroke.